Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Continuing Forward With Innovation and Progress in US Healthcare
May 22, 2017
Dr Gail Wilensky: Senate Health Bill Will Be to the Left of the House
May 22, 2017
Currently Reading
Accounting for Stakeholder Preferences in Value Assessments
May 22, 2017
Negotiating Successful Outcomes-Based Contracts
May 23, 2017
Dr Ilene Hollin: Tailored Approach to Value Assessment Is Necessary
May 23, 2017
Influencing Untreated Individuals Through Their Social Networks
May 23, 2017
Dr Steve Pearson Outlines the Importance of Thresholds on Determining Value
May 23, 2017
The Realities and Challenges of Medicare Negotiating Drug Prices
May 24, 2017
Dr Patricia Danzon: Cost-Effectiveness Thresholds Create Incentive to Develop Better Drugs
May 24, 2017
Gene Therapies Present Great Potential, but Also Ethical and Practicality Challenges
May 24, 2017
Dr James D. Chambers Talks Future Health Economics Trends He Is Watching
May 24, 2017
Dr Gail Wilensky Remains "Hopeful" for Bipartisan Legislation on Healthcare Reform
May 29, 2017
Dr David Cutler: Won't Be Easy for Senate Republicans to Create a Healthcare Bill
May 30, 2017
Not Enough Attention Paid to Low Healthcare Spending Growth
June 13, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017
Dr Scott Ramsey on Challenges of Determining Cost Effectiveness of Novel Cancer Treatments
June 19, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017

Accounting for Stakeholder Preferences in Value Assessments

Laura Joszt
Stakeholders’ perspectives can vary, and their different preferences matter when it comes to value assessment, but only if the right questions are being asked.
Stakeholder preferences matter when it comes to value assessment, but only if the right questions are being asked.

In a panel discussion at the ISPOR 22nd Annual International Meeting, held May 20-24 in Boston, Massachusetts, Ilene Hollin, PhD, MPH, of the National Pharmaceutical Council, discussed differences in how stakeholders prioritize value inputs; Eleanor Perfetto, PhD, RPh, MS, of the National Health Council, highlighted ways to incorporate patient inputs into decision-making frameworks; and Michael S. Sherman, MD, MBA, MS, of Harvard Pilgrim Health Care, discussed the payers perspective of incorporating patient-centered inputs into decision making.

"Different stakeholder groups view value in different ways," Hollin said in an interview with The American Journal of Managed Care®. "Patients, for instance, when they think about value, they’re thinking about, 'How does this therapy help me achieve my life objectives?' Payers, on the other hand, are thinking about value and then designing coverage policies accordingly in terms of how to give patients access to the therapies that meet those life objectives."

One of the biggest issues is the lack of useful data. According to Perfetto, there is no data on what is most important to patients. In addition, there has been a focus on very clinical endpoints instead of the kind of goals that patients are most interested in.

“If we don’t have information from patients on what’s most important to them, and even if we did find out what is most important to them, we don’t know which treatments can meet that need,” Perfetto said.

Sherman prefaced his presentation by saying that among the discussions about pricing and access, it’s important to remember that the stakeholders—insurers, pharmaceutical companies, providers, etc—are there to treat patients.

He provided the example that at Harvard Pilgrim there are value-based agreements for orthopedics, but the outcome measures tend to be high level—satisfaction, readmission, etc—but the things that are most important, such as range of motion or pain, are not usually part of the agreements because they are hard to collect as measures.

“Which is a lousy excuse, but we have lot of work to do in other areas, which is my point,” he said.

Harvard Pilgrim has embraced a number of value frameworks, but having used them, there are 2 main issues: they only cover a small number of drugs and they’re not all actionable. Unfortunately, Sherman isn’t sure if the second issue will change.

“Frameworks are helpful, but it doesn’t always lead to something that is actionable for a payer,” he said. Also, these frameworks are not necessarily patient-centered. The area is ripe for innovation, he added.

Hollin explained that stakeholder preferences, particularly patient preferences can be better incorporated into value assessments by thinking about it earlier in the development stages of the framework. This involves ensuring that the developer is looking at the right clinical endpoints that matter to patients and that what is being measured is important to them.

“Once we have those types of preferences they can be better incorporated into value assessments,” Hollin said. This provides the ability to offer a range that accounts for a variety of preferences.

Perfetto added that current frameworks rely heavily on randomized controlled trial data, and that should not be the case.

“We’re letting the data drive the model and it may be that it’s the wrong input that we started with in the first place,” she said.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up